Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib

• Published in: Journal of B.U. ON. Vol. 18; no. 3; p. 775
• Main Authors: Sen, F, Yildiz, I, Basaran, M, Ekenel, M, Oz, F, Kilic, L, Toz, B, Gurdal, A, Camlica, H, Bavbek, S, Oflaz, H
• Format: Journal Article
• Language: English
• Published: Greece 01.07.2013
• Subjects: Adult; Aged; Antineoplastic Agents - adverse effects; Blood Flow Velocity - drug effects; Blood Sedimentation - drug effects; Carcinoma, Renal Cell - complications; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - secondary; Cardiovascular Diseases - chemically induced; Cardiovascular Diseases - pathology; Case-Control Studies; Coronary Circulation - drug effects; Cross-Sectional Studies; Echocardiography, Doppler; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors - complications; Gastrointestinal Stromal Tumors - drug therapy; Gastrointestinal Stromal Tumors - pathology; Humans; Indoles - adverse effects; Kidney Neoplasms - complications; Kidney Neoplasms - drug therapy; Kidney Neoplasms - pathology; Male; Middle Aged; Prognosis; Pyrroles - adverse effects
• ISSN: 1107-0625

Hypertension is one of the major side effects of sunitinib, an angiogenesis inhibitor used in the treatment of metastatic renal cell carcinomas (mRCC) and gastrointestinal stromal tumors (GIST). Endothelial dysfunction, an early and reversible event in the pathogenesis of atherosclerosis, is suggested to be one of the possible underlying mechanisms of hypertension caused by angiogenesis inhibitors. Coronary flow reserve (CFR) measurement by trans-thoracic Doppler echocardiography (TTDE) reflects coronary microvascular and endothelial functions, as a cheaper and an easy screening test. We have used TTDE to evaluate endothelial function and coronary microvascular function in mRCC and GIST patients under sunitinib treatment. Eighteen metastatic cancer patients (16 mRCC and 2 GIST) on sunitinib treatment and 27 healthy subjects were enrolled in this cross-sectional study. Thyroid stimulating hormone (TSH), lipid profile, creatinine, hemoglobin, glucose, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), anthropometric and physical parameters of patients were recorded. CFR recordings were performed by the Vivid 7 echocardiography device. CFR was significantly lower in patients when compared with controls (1.82±0.4 vs 2.71±0.8, respectively; p < 0.001). Impaired CFR was found in 13 (72%) patients whereas all controls had normal CFR values. CFR was inversely correlated with the duration of sunitinib treatment (r=-0.36, p =0.01), high sensitivite (hs) CRP (r = -0.574, p =0.01) and ESR (r = - 0.5, p = 0.02). Our findings indicate that CFR is significantly impaired in cancer patients on sunitinib treatment. There is an inverse correlation between CFR and duration of sunitinib treatment and inflammation markers.